Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate

作者：Posadas Herrera Guillermo; Inoue Shingo; Fuke Isao; Muraki Yuko; Mapua Cynthia A; Khan Afjal Hossain; Parquet Maria del Carmen; Manabe Sadao; Tanishita Osamu; Ishikawa Toyokazu; Natividad Filipinas F; Okuno Yoshinobu; Hasebe Futoshi; Morita Kouichi^*

来源：Vaccine, 2010, 28(50): 7939-7946.

DOI：10.1016/j.vaccine.2010.09.076

• West Nile Virus
• Formalin-inactivated vaccine
• Vaccine Efficacy Test
• Cross-neutralization test

A formalin-inactivated West Nile Virus (WNV) vaccine (WN-VAX) derived from the WNV-NY99 strain was tested for its safety, efficacy, dilution limit for complete protection, and cross-neutralization. Safety tests performed with experimental animals, bacteria, or cultured cell lines showed no evidence of short-or long-term adverse effects. WN-VAX also protected 100% of 4-week-old mice against a lethal challenge from the WNV-NY99 strain after two doses of intraperitoneal inoculation even when the vaccine was diluted to 3.2 ng/dose. Moreover, very limited cross-neutralization activity against Japanese encephalitis virus, Dengue virus, Murray Valley encephalitis virus, Yellow fever virus or St. Louis encephalitis virus was observed. Therefore, the WN-VAX satisfies the requirements for human trials planned to be done in Japan.

• 出版日期2010-11-23